Irma Herrera-Camacho

Prof. Dr. Irma Herrera-Camacho

orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2019 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
FSFabiola Lilí Sarmiento-Salinas
Fabiola Lilí Sarmiento-Salinas
ADAlam Delgado-Magallón
Alam Delgado-Magallón
JMJosé Benito Montes-Alvarado
José Benito Montes-Alvarado
DRDALIA RAMIREZ
DALIA RAMIREZ
JFJuan Carlos Flores-Alonso
Juan Carlos Flores-Alonso
Paola MaycottePaola Maycotte
Paola Maycotte
Due to their crucial role in cell metabolism and homeostasis, alterations in mitochondrial biology and function have been related to the progression of diverse diseases including cancer. One of the consequences associated to mitochondrial dysfunction is the production of reactive oxygen species (ROS). ROS are known to have a controversial role during cancer initiation and progression and although several studies have tried to manipulate intracellular ROS levels using antioxidants or pro-oxidation conditions, it is not yet clear how to target oxidation for cancer therapy. In this study, we found differences in mitochondrial morphology in breast cancer cells when compared to a non-tumorigenic cell line and differences in mitochondrial function among breast cancer subtypes when exploring gene-expression data from the TCGA tumor dataset. Interestingly, we found increased ROS levels in triple negative breast cancer (TNBC) cell lines and a dependency on ROS for survival since antioxidant treatment induced cell death in TNBC cells but not in an estrogen receptor positive (ER+) cell line. Moreover, we identified the mitochondria as the main source of ROS in TNBC cell lines. Our results indicate a potential use for ROS as a target for therapy in the TNBC subtype which currently has the worst prognosis among all breast cancers and remains as the only breast cancer subtype which lacks a targeted therapy.

1 July 2019 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
CMCarolina Jasso Miranda
Carolina Jasso Miranda
IHIrma Herrera-Camacho
Irma Herrera-Camacho
LFLilian Karem Flores-Mendoza
Lilian Karem Flores-Mendoza
FDFabiola Domínguez
Fabiola Domínguez
VVVerónica Vallejo-Ruiz
Verónica Vallejo-Ruiz
JRJulio Reyes-Leyva
Julio Reyes-Leyva
Background: There is a lack of specific antiviral therapy against dengue virus (DENV) in current use. Therefore, a great proportion of dengue cases progress to severe clinical forms due to a complex interplay between virus and host immune response. It has been hypothesized that heterotypic non-neutralizing antibodies enhance DENV infection in phagocytic cells, and this induces an inflammatory response that is involved in the pathogenesis of severe dengue. Purpose: To identify the antiviral and immunomodulatory effects of polyphenols on dengue virus infection. Methods: Human U937-DC-SIGN macrophages were infected with DENV serotypes 2 or 3 in the presence or not of enhancing antibody 4G2. Viral titers and the secretion of tumor necrosis factor-alpha, IL-6, IL-10 and interferon-alpha were analyzed timely. Results: DENV infection alone induced high production of IL-6 and TNF-α, but in the presence of 4G2 antibody, viral titers and TNF-α secretion were potentiated. Based on anti-inflammatory antecedents, the polyphenols curcumin, fisetin, resveratrol, apigenin, quercetin and rutin were tested for antiviral and immunomodulatory properties. Only quercetin and fisetin inhibited DENV-2 and DENV-3 infection in the absence or presence of enhancing antibody (>90%, p<0.001); they also inhibited TNF-α and IL-6 secretion (p<0.001). Conclusion: Quercetin and fisetin down-regulate the production of proinflammatory cytokines induced by DENV infection enhanced by antibodies a mechanism involved in severe dengue.

28 September 2015 in Virology Journal
Verified
Journal Article
Open access
PDF file
HPHelen K. Palma-Ocampo
Helen K. Palma-Ocampo
JFJuan C. Flores-Alonso
Juan C. Flores-Alonso
VVVerónica Vallejo-Ruiz
Verónica Vallejo-Ruiz
JRJulio Reyes-Leyva
Julio Reyes-Leyva
LFLilian Karem Flores-Mendoza
Lilian Karem Flores-Mendoza
Gerardo Santos-LopezGerardo Santos-Lopez
Gerardo Santos-Lopez
In viral disease, infection is controlled at the cellular level by type I interferon (IFN-I), but dengue virus (DENV) has the ability to inhibit this response. Type III interferon, also known as lambda IFN (IFN-III or IFN-λ), is a complementary pathway to the antiviral response by IFN-I. This work analyzed the IFN-λ (IFN-III) mediated antiviral response against DENV serotype 2 (DENV-2) infection. Dengue fever patients were sampled to determine their IFN-λ levels by ELISA. To study the IFN-λ response during DENV infection we selected the epithelial cell line C33-A, and we demonstrated that it is permissive to DENV-2 infection. The effect of IFN-λ on virus replication was determined in these cells, in parallel to the expression of IFN-stimulated genes (ISGs), and Suppressor of Cytokine Signaling (SOCS), genes measured by RT-qPCR. We found increased (~1.8 times) serological IFN-λ in dengue fever patients compared to healthy blood donors. IFN-λ inhibited DENV-2 replication in a dose-dependent manner in vitro. The reduction of viral titer corresponded with increased ISG mRNA levels (MX1 and OAS1), with the highest inhibition occurring at ISG’s peak expression. Presence of IFN-negative regulators, SOCS1 and SOCS3, during DENV-2 infection was associated with reduced IFN-λ1 expression. Evidence described here suggests that IFN-λ is a good candidate inhibitor of viral replication in dengue infection. Mechanisms for the cellular and organismal interplay between DENV and IFN- λ need to be further studied as they could provide insights into strategies to treat this disease. Furthermore, we report a novel epithelial model to study dengue infection in vitro.

4 July 2019 in Expert Opinion on Therapeutic Patents
Verified
Journal Article
Closed access
IHIrma Herrera-Camacho
Irma Herrera-Camacho
MAMaricruz Anaya-Ruiz
Maricruz Anaya-Ruiz
Martin Perez-SantosMartin Perez-Santos
Martin Perez-Santos
LPLourdes Millán-Pérez Peña
Lourdes Millán-Pérez Peña
Cindy BandalaCindy Bandala
Cindy Bandala
GLGerardo Landeta
Gerardo Landeta
Introduction: TIM3 and PD-1 are checkpoint inhibitors in cancer that coordinate the downregulation of the proliferation of antigen-specific lymphocytes. There is a great need to discover and develop new therapies focused on inhibiting the action of TIM3 and PD-1, and consequently improving the immune response in the various types of cancer. Authors of patent EP3356411A1 propose several anti-TIM3/anti-PD-1 bispecific antibodies, as well as the method for producing them and their pharmacological application in the treatment of cancer. Areas covered: Patent EP3356411A1 describes a method by producing anti-TIM3/anti-PD-1 bispecific antibodies, and their potential in cancer treatment. Expert opinion: Data supporting the patent demonstrate the ability by producing anti-TIM3/anti-PD-1 bispecific antibodies. Although the proposed methodology is very interesting and promising, further studies are necessary to assess the clinical applicability of the inventions on cancer.

1 February 2009 in The Brazilian Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
Gerardo Santos-LopezGerardo Santos-Lopez
Gerardo Santos-Lopez
TSThomas Scior
Thomas Scior
MBMaría del Tránsito Borraz-Argüello
María del Tránsito Borraz-Argüello
VVVerónica Vallejo-Ruiz
Verónica Vallejo-Ruiz
IHIrma Herrera-Camacho
Irma Herrera-Camacho
JRJulio Reyes-Leyva
Julio Reyes-Leyva
A point mutation from guanine (G) to adenine (A) at nucleotide position 1081 in the hemagglutinin-neuraminidase (HN) gene has been associated with neurovirulence of Urabe AM9 mumps virus vaccine. This mutation corresponds to a glutamic acid (E) to lysine (K) change at position 335 in the HN glycoprotein. We have experimentally demonstrated that two variants of Urabe AM9 strain (HN-A1081 and HN-G1081) differ in neurotropism, sialic acidbinding affinity and neuraminidase activity. In the present study, we performed a structure-function analysis of that amino acid substitution; the structures of HN protein of both Urabe AM9 strain variants were predicted. Based on our analysis, the E/K mutation changes the protein surface properties and to a lesser extent their conformations, which in turn reflects in activity changes. Our modeling results suggest that this E/K interchange does not affect the structure of the sialic acid binding motif; however, the electrostatic surface differs drastically due to an exposed short alpha helix. Consequently, this mutation may affect the accessibility of HN to substrates and membrane receptors of the host cells. Our findings appear to explain the observed differences in neurotropism of these vaccine strains

9 November 2021 in Revista Mexicana de Ciencias Pecuarias
Verified
Journal Article
Open access
PDF file
JBJOSE FRANCISCO RIVERA BENITEZ
JOSE FRANCISCO RIVERA BENITEZ
JLJazmín De la Luz-Armendáriz
Jazmín De la Luz-Armendáriz
LGLuis Gómez-Núñez
Luis Gómez-Núñez
FVFernando Diosdado Vargas
Fernando Diosdado Vargas
GEGuadalupe Socci Escatell
Guadalupe Socci Escatell
MMManuel Zapata Moreno
Manuel Zapata Moreno
En los sistemas de producción porcina, uno de los puntos críticos que deben ser atendidos con estricto rigor, es la salud de los cerdos. La salud, es un componente estructural del bienestar animal y refleja un estado óptimo de los animales, lo que repercute directamente en un mayor desempeño productivo y mejores condiciones de desarrollo. Uno de los eslabones más frágiles de la salud de los cerdos, es la presencia de enfermedades infecciosas más importantes, las cuales pueden representar pérdidas hasta del 100 % de la producción, por lo cual, debe ser un tema de atención constante, y continuamente vigilado por el Médico Veterinario Zootecnista y los productores, en perfecta coordinación con las autoridades sanitarias oficiales. En la actualidad, la implementación de mejores prácticas en la cadena productiva es de interés para productores y consumidores. El control de las enfermedades infecciosas debe ser un tema de colaboración entre los diferentes actores del entorno y ser considerado un bien público, ya que las repercusiones negativas, pueden ser desde el nivel local hasta mundial. En la presente revisión, se abordará la temática relacionada con las principales enfermedades infecciosas que ponen en riesgo la salud porcina, el impacto, las principales aportaciones realizadas por el Instituto Nacional de Investigaciones Forestales, Agrícolas y Pecuarias (INIFAP) en sus 35 años de vida, específicamente en el Centro Nacional de Investigación Disciplinaria en Salud Animal e Inocuidad (CENID-SAI), anteriormente conocido como el emblemático CENID-Microbiología o Palo Alto.